Table 8 Overall response rate and PFS in 4 randomized trials comparing gemcitabine to gemcitabine plus other cytotoxic agent
Reference | Year | n | Treatment regimen | ORR (%) | p | Median PFS/TTP (mo) | p |
|---|---|---|---|---|---|---|---|
Oettle | 2005 | 282 | Gemcitabine | 7.1 | 0.004 | 3.3 | 0.111 |
| Â | Â | 283 | Gemcitabine + Pemetrexed | 14.8 | Â | 3.9 | Â |
Rocha Lima | 2004 | 180 | Gemcitabine | 4.4 | < 0.001 | 3.0 | 0.352 |
| Â | Â | 180 | Gemcitabine + Irinotecan | 16.1 | Â | 3.5 | Â |
Stathopoulos | 2006 | 70 | Gemcitabine | 10 | 0.387 | 2.9 | 0.795 |
| Â | Â | 60 | Gemcitabine + Irinotecan | 15 | Â | 2.8 | Â |
O'Reilly | 2004 | 174 | Gemcitabine | 7.1 | -- | 3.8 | 0.22 |
| Â | Â | 175 | Gemcitabine + Exatecan | 8.2 | Â | 4.1 | Â |